FDA-approved
Digestive & weight
Enlicitide
Evidence
FDA approved
Class
Oral macrocyclic PCSK9 inhibitor peptide
KEY TAKEAWAY
Enlicitide is an oral macrocyclic peptide designed to block PCSK9, a protein that reduces the liver's ability to clear LDL cholesterol. It is sold as Lipfendra. The FDA approved enlicitide (Lipfendra) in July 2026 as the first oral PCSK9 inhibitor, for adults with high cholesterol alongside diet and exercise.
Written by the Veylo editorial team · Updated
November 2026
What it is
Oral macrocyclic PCSK9 inhibitor peptide
Approved for
High LDL cholesterol, including heterozygous familial hypercholesterolemia
Key fact
The FDA approved enlicitide (Lipfendra) in July 2026 as the first oral PCSK9 inhibitor, for adults with high cholesterol alongside diet and exercise.
Route
One 20 mg tablet once a day
Evidence strength
FDA approved
Enlicitide is an oral macrocyclic peptide designed to block PCSK9, a protein that reduces the liver's ability to clear LDL cholesterol. It is sold as Lipfendra.
By blocking PCSK9, it leaves more LDL receptors on liver cells to pull LDL cholesterol out of the blood.
The FDA approved enlicitide (Lipfendra) in July 2026 as the first oral PCSK9 inhibitor, for adults with high cholesterol alongside diet and exercise.
High LDL cholesterol, including heterozygous familial hypercholesterolemia.
In one pivotal trial diarrhea and dizziness were more common with enlicitide than with placebo. Data on heart attacks and strokes are still awaited.
U.S. FDA prescribing information for Enlicitide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.